The two findings elucidate a practical aspect for the clinical management of patients with lung cancer, as they demonstrate a clear indication that EGFR mutational analysis may be performed in small tissue samples obtained by biopsy methods on either primary or secondary tumour lesions, thus, avoiding the invasiveness of surgical approaches. The gene discussed is EGFR; the disease is neoplasm.